Nav: Home

Older melanoma patients may respond to anti-PD1 immunotherapy better than younger patients

June 13, 2018

Bottom Line: With each decade of life, the likelihood of progression of melanoma after treatment with anti-PD1 immunotherapy decreased by 13 percent.

Journal in Which the Study was Published:Clinical Cancer Research, a journal of the American Association for Cancer Research.

Author: Ashani T. Weeraratna, PhD, the Ira Brind professor and co-program leader of the Immunology, Microenvironment and Metastasis Program at The Wistar Institute; and a member of Wistar's Melanoma Research Center in Philadelphia

Background: "We wanted to study how the aging microenvironment affects response to immunotherapy, and much to our surprise, the effect was exactly the opposite of what we learned with targeted therapy," said Weeraratna. Prior research by Weeraratna and colleagues had shown that the tumor microenvironment in older patients promoted melanoma metastasis and resistance to targeted therapy with a BRAF inhibitor.

How the Study Was Conducted and Results: In this multinational study, the researchers analyzed data from 538 patients with melanoma treated with the anti-PD1 therapy pembrolizumab (Keytruda) at eight different institutes worldwide. Of the patients, 238 were younger than 62 years. They found that 50 percent of patients younger than 62 years, compared with only 37 percent of patients 62 years or older, had poor response to the treatment. This finding was independent of gender or prior treatment with MAPK inhibitor (MAPKi) therapies.

"Interestingly, younger patients who had prior MAPKi therapy had a much lower rate of complete response to anti-PD1 than older patients who had prior MAPKi therapy (4 percent versus 15 percent)," Weeraratna said.

Weeraratna and colleagues conducted further experiments using mice bearing melanoma to understand the relationship between the aging microenvironment and response to anti-PD1 immunotherapy. The results from the studies with mice were in agreement with those from human patients: Young mice were more resistant to anti-PD1 therapies than aged mice. The results were also independent of tumor mutational burden, because both young and aged mice were implanted with genetically identical tumors but had different outcomes.

Further research revealed differences in the immune microenvironment of the two groups of mice. A subpopulation of T cells that are known to be immunosupressive, FOXP3-positive Tregs, were fewer in older mice compared with younger mice.

The team analyzed primary and metastatic melanoma samples from another cohort of 268 patients for the presence of the protein FOXP3 in T cells and found that the FOXP3-positivity of intratumoral T cells decreased in patients over 50 years of age. The researchers also observed age-related differences in the T-cell subpopulations within the tumors of these patients.

Her team found that in young mice, combining anti-PD1 with an anti-CD25 antibody therapy, which depletes Tregs, yielded response rates comparable to those seen in older mice.

Author's Comments: "Our current study showed that for each decade of life, patients with melanoma had a 13 percent lower chance of having a negative outcome following anti-PD1 immunotherapy," Weeraratna noted.

"Our results suggest that preconditioning the tumor microenvironment in younger patients by depleting Tregs could make them respond to anti-PD1 immunotherapies better," she said. "Our studies suggest that in designing therapies for melanoma, age should be considered as a factor in both preclinical and clinical models."

"Age has a huge impact on patients' response to therapy and tumor progression," Weeraratna noted. "Researchers conducting preclinical studies should ensure that the age of the mice reflects the age of the patients the treatments are intended for, as these studies form the basis for drug development and human clinical trials."

Study Limitations: As limitations to the study, the researchers were unable to perform multivariate analyses and could not control for tumor mutational burden in their studies with melanoma patients, Weeraratna said.
-end-
Funding & Disclosures: This study was supported by the National Institutes of Health, a Cancer Institute NSW fellowship (Australia), a Melanoma Research Alliance/L'Oréal Paris-USA Women in Science Team Science Award, an Established Investigator Award from the Melanoma Research Foundation, an ASCO/CCF Career Development Award, and a Melanoma Research Alliance Young Investigator grant. Weeraratna declares no conflicts of interest.

American Association for Cancer Research

Related Melanoma Articles:

Immunity against melanoma is only skin deep
Researchers at Dartmouth's Norris Cotton Cancer Center find that unique immune cells, called resident memory T cells, do an outstanding job of preventing melanoma in patients who develop the autoimmune disease, vitiligo.
Researchers document how melanoma tumors form
University of Iowa researchers have documented in continuous, real time how melanoma cells form tumors.
New driver, target in advanced mucosal melanoma
A University of Colorado Cancer Center study published March 15, 2017, in the journal Melanoma Research uses the unique resource of over 600 melanoma samples collected at the university to demonstrate, for the first time, novel mutations involved in mucosal melanoma, paving the way for therapies to treat this overlooked subtype.
NIH study reveals how melanoma spreads
Newly identified genes and genetic pathways in primary melanoma -- a type of skin cancer -- could give researchers new targets for developing new personalized treatments for melanoma, and potentially other cancers.
Melanoma research breakthrough gives hope to treatment
A QUT-driven project has identified the way in which melanoma cells spread, opening up new pathways to treatment via drugs to 'turn off' the invasive gene.
Study examines melanoma incidence, death
A new research letter published online by JAMA Dermatology updates information on trends in melanoma incidence and death in the United States since 2009.
Research providing promising new treatments for melanoma
In a paper published online Nov. 30, 2016, in Melanoma Management, Adam Riker, M.D., Professor of Surgery and Chief of Surgical Oncology at LSU Health New Orleans School of Medicine, reviews approaches to manage melanoma, including one tested at LSU Health New Orleans that provoked a complete response in a patient with a long history of the disease.
A protein that defines the melanoma blueprint
The latest study of the Melanoma Group at the Spanish National Cancer Research Centre describes the roles of CPEB4; a protein that is crucial for melanoma cell survival.
Nanotechnology supports treatment of malignant melanoma
Changes in the genetic make-up of tissue samples can be detected quickly and easily using a new method based on nanotechnology.
Detecting melanoma early, without a biopsy
Colorado State University Professor Jesse Wilson has received a one-year, $30,000 grant from the Colorado Clinical and Translational Sciences Institute to develop a new microscope that can distinguish between benign and malignant pigmented skin lesions, without the need for biopsy.

Related Melanoma Reading:

Melanoma: A Modern Multidisciplinary Approach
by Adam I. Riker (Editor)

This text serves as a very useful clinical guide and realistic approach to the clinical management of melanoma. Primary care physicians, specialists from varying areas of medical practice and numerous other healthcare providers will find this text to be quite useful as a standard daily reference and use in the office setting. It provides a clear and concise source of information in order to make real-life, evidence-based decisions for all aspects of management for cutaneous melanoma. This book also provides the latest breakthroughs in melanoma research, ranging from recent discoveries in... View Details


Melanoma- Not Just Skin Cancer
by Catherine M. Poole (Author)

All cancer diagnoses are terrifying, but a melanoma diagnosis is both frightening and confusing. When Catherine M. Poole learned she had melanoma twenty-five years ago, she found that most of the literature on melanoma focused on prevention. To add to her understandable alarm, she couldn’t find clear, concise information on treatment options. Poole wanted to be an informed patient, but she had no resources.

She survived melanoma and has become a dedicated activist for melanoma research and a staunch patient advocate. Her new book, Melanoma: Not Just Skin Cancer, is a... View Details


Melanoma without a Cause: How the New Miracle Immunotherapy Drugs and My Own Immune System Helped Me Fight Stage Four Cancer
by Bryant Wieneke (Author)

Melanoma without a Cause: How the New Miracle Immunotherapy Drugs and My Own Immune System Helped Me Fight Stage Four Cancer is a tale of survival following a devastating diagnosis of metastatic melanoma. Fighting through some heavy side effects, the author is saved by a treatment not available even a few years ago. He is given immunotherapy drugs, which stimulate his immune system to target and destroy the cancer cells that have spread throughout his body. Melanoma with a Cause chronicles the author’s treatment and remarkable turnaround, but remission remains elusive. A blog has been... View Details


Beating Melanoma: A Five-Step Survival Guide (A Johns Hopkins Press Health Book)
by Steven Q. Wang MD (Author)

Dr. Steven Q. Wang, a world-renowned skin cancer expert, provides an essential guide for people with melanoma and their families.

The book’s unique, practical format approaches the disease in two phases, just as people with melanoma need to do. First comes a step-by-step guide for what Dr. Wang calls the "mad rush" phase―an intense and stressful period from diagnosis to completing initial treatment. Dr. Wang's calm guidance helps readers through this critical time, using an easy to understand plan for ensuring optimal treatment and survival outcomes. Once the mad rush phase is... View Details


Healing Melanoma - The Gerson Way
by Charlotte Gerson (Author)

This booklet introduces Dr. Max Gerson and the founding principal of the Gerson Therapy, that Melanoma and most chronic diseases are able to manifest in the body because of toxicity and nutritional deficiency. Charlotte Gerson gives an overview of the Gerson Therapy and reviews some of the methods used in the program. Also included are case histories of individuals confronted with Melanoma and how they overcame then using the Gerson Therapy.

View Details


Melanoma: It Started With a Freckle
by David L. Stanley (Author)

With "Melanoma: It Started with a Freckle", David L. Stanley invites you to join him on an inside tour of his cancer. You'll travel with Stanley from the dimly lit and elegantly decorated office of the dermatologist to the fluorescent glare of the operating room theater and back to the workplace as he faces up to melanoma, the only major cancer that has seen its incidence rise since 2000, with humor, humility, and a deep understanding of the disease borne of research and science. In a memoir that speaks to anyone who has bumped up against a major health scare, Stanley offers up an engaging... View Details


The Melanoma Book: A Complete Guide to Prevention and Treatment, Including theEarly DetectionSelf-Exam Body Map
by Howard L. Kaufman (Author)

Citing high rates of cures that can be achieved with early detection, a whole-life plan informs readers on how to best enable melanoma skin cancer's immediate detection and select the most compatible and effective treatment options. Original. View Details


Melanoma
by Jonathan S. Zager (Editor), Vernon K. Sondak (Editor), Ragini Kudchadkar (Editor)

Melanoma is a concise handbook that identifies best-practice guidelines and presents the most current procedures for the diagnosis and management of melanoma in a succinct and easy-to-read manner. Chapters cover melanoma pathology, biopsy techniques, staging and risk stratification, surgical treatment of localized melanoma, immunotherapy, radiation therapy, and guidelines for resected melanoma, targeted therapy, cytotoxic chemotherapy, and management of brain metastases, mucosal and ocular melanoma, and pediatric melanoma patients. This handbook is a must-have tool for clinicians... View Details


A Melanoma Patient's Survival Guide: Lemons Really Do Make Lemonade: You Just Have to Add a Little Sugar
by Sally Welsh (Author)

A Melanoma Patient’s Survival guide: Lemons Really Do Make Lemonade is an effort to bring awareness to the subject of melanoma. This insidious disease is being diagnosed in over 50,000 people a year in the United States alone. Melanoma will affect one in seventy-five people in California. That rate goes up each year. Melanoma can be a silent killer. This heart-warming book was written by a survivor of serious melanoma, Sally Welsh. Sally has shared her experience with thousands of people, and has prepared this book with the hope of making your journey a little easier. Her suggestions deal... View Details


Melanoma Messed With the Wrong Person: Blank Lined Journal - 6x9 - Gift for Melanoma Patient or Melanoma Survivor
by Passion Imagination Journals (Author)

Are you looking for a beautiful, humorous gift for someone who has Melanoma or a Melanoma survivor?

This is a blank, lined journal that makes a perfect present for friends and family, male or female. Other features of this notebook include:

110 pages6x9 inchesExcellent and thick bindingDurable white paperSleek, matte-finished cover for a professional look
This diary is a convenient and perfect size to carry anywhere for writing, journaling and note taking. If you would like an unlined journal or a different cover, please take a look at our other... View Details

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

The Person You Become
Over the course of our lives, we shed parts of our old selves, embrace new ones, and redefine who we are. This hour, TED speakers explore ideas about the experiences that shape the person we become. Guests include aerobatics pilot and public speaker Janine Shepherd, writers Roxane Gay and Taiye Selasi, activist Jackson Bird, and fashion executive Kaustav Dey.
Now Playing: Science for the People

#478 She Has Her Mother's Laugh
What does heredity really mean? Carl Zimmer would argue it's more than your genes along. In "She Has Her Mother’s Laugh: The Power, Perversions, and Potential of Heredity", Zimmer covers the history of genetics and what kinship and heredity really mean when we're discovering how to alter our own DNA, and, potentially, the DNA of our children.